Drug Trial Radar · NCT07928388
Continuation Study With Oral MC-1 for Treatment of Patients With PNPO-Deficiency
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Jul 15, 2025
Primary completion
Jul 15, 2029
Study completion Jul 15, 2029
Sponsor
- Lead sponsor
- MedicureIndustry
- Sponsor type
- Industry
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Continued access to MC-1 is required by subjects who have participated in the MEND-PNPO study, as no other pharmaceutical grade P5P is currently commercially available. The protocol duration is planned for until the finished product is commercially available in the respective countries where subjects are participating in the study.
Conditions
- Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Interventions
Pyridoxal 5'-PhosphateDrug
Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: Through study completion, up to 4 years
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Lucile Packard Children's Hospital
Palo Alto, California · Active not recruiting
Children's Hospital Colorado
Aurora, Colorado · Active not recruiting
Boston Children's Hospital
Boston, Massachusetts · Active not recruiting
Queensland Children's Hospital and Health Service
Brisbane, Queensland, Australia · Recruiting
Royal Children's Hospital
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.